Comparative Pharmacology
Head-to-head clinical analysis: PREDNISOLONE EYE DROPS versus PREDSULFAIR II.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREDNISOLONE EYE DROPS versus PREDSULFAIR II.
Prednisolone Eye Drops vs PREDSULFAIR II
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators such as prostaglandins and leukotrienes.
Prednisolone is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators. Sulfonamide component provides bacteriostatic action via inhibition of dihydropteroate synthase in bacterial folate synthesis.
Instill 1-2 drops into the conjunctival sac of the affected eye(s) four times daily. In severe cases, dosing may be initiated with 1-2 drops every 1-2 hours and tapered upon improvement.
1-2 drops into the affected eye(s) every 4-6 hours; not to exceed 6 doses per day.
None Documented
None Documented
Plasma: 2-4 hours; tissue effects persist 18-36 hours. Clinically, duration of adrenal suppression may exceed plasma half-life.
Terminal elimination half-life of prednisolone (active moiety): 2.1-3.5 hours; clinical context: duration of HPA axis suppression exceeds plasma half-life (12-36 hours).
Renal (primarily as metabolites): ~70% after oral dose; unchanged drug: <20%. Biliary/fecal: minor.
Renal: 70-80% (30-50% as unchanged prednisolone, 20-30% as prednisone and inactive metabolites); Biliary/Fecal: 15-20%
Category A/B
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Sulfonamide Combination